FDA grants approval via accelerated approval pathway to ELEVIDYS: First-ever gene therapy for individuals with Duchenne ages 4-5 ...
Santhera announces exclusive North America license agreement with Catalyst Pharmaceuticals for vamorolone ...
PPMD publishes results of study to understand Duchenne patients’ and caregivers’ perspectives on corticosteroids ...